The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Open accessAbstract
SUMMARY While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole genome and transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor / 38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kilobases upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most PCas express AR throughout the course of the disease2–5”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, deep deletions (primarily of BRCA2; Supplementary Fig. 23) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations28.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · cited 1×
“While over 160,000 American men are diagnosed with prostate cancer each year, <20% of patients will experience progression to the lethal form of the disease, termed metastatic castration-resistant prostate cancer (mCRPC) (Siegel et al., 2018).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724 · cited 2×
“2.0 Zhang et al., 2013 https://cran.r-project.org/web/packages/RCircos/index.html ANNOVAR v2018Apr16 Wang et al., 2010 http://annovar.openbioinformatics.org/en/latest/ Cell 174, 1–12.e1–e3, July 26, 2018 e1 Please cite this article in press as: Quigley et al., Genomic Hallmarks and Structural…”
InfluentialCingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Ohno, S. (1970) · doi:10.1007/978-3-642-86659-3 · Cited by 7,833
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 3×
“We observed mutually exclusive fusions activating the ETS family members ERG, ETV1, ETV4, and ETV5 in 59% of our cohort (Figure 1C; fusions listed in Table S3).”
InfluentialSelf-citation
Flagged first, then by citations
1 of the 73 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R. J., Syndikus, I., Ralph, C., Jain, S., Varughese, M. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 643
Structural variation in the sequencing era
Ho, S. S., Urban, A. E., & Mills, R. E. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0180-9 · Cited by 630
Sandhu, S. K., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 632
Pan-cancer landscape of homologous recombination deficiency.
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020) · Nature communications · doi:10.1038/s41467-020-19406-4 · Cited by 532
“However, deep deletions (primarily of BRCA2; Supplementary figure 20) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations[29].”
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W. T., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., Marzo, A. M. D., Nelson, P. S., & Yegnasubramanian, S. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 544
Safran, M., Rosen, N., Twik, M., Barshir, R., Stein, T. I., Dahary, D., Fishilevich, S., & Lancet, D. (2021) · Springer eBooks · doi:10.1007/978-981-16-5812-9_2 · Cited by 492
“…of regulatory elements and their gene targets, has been used by the community as an annotation standard for enhancers and promoters in the human genome, as well as for the associations of those elements with their gene targets (Quigley et al. 2018; Zhang et al. 2018; Holzinger et al. 2017; Fig.”
Biologically informed deep neural network for prostate cancer discovery
Elmarakeby, H. A., Hwang, J., Arafeh, R., Crowdis, J., Gang, S., Liu, D., AlDubayan, S. H., Salari, K., Kregel, S., Richter, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03922-4 · Cited by 456
Hormonal Therapy for Prostate Cancer
Desai, K. B., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 475
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Guan, X., Polesso, F., Wang, C., Sehrawat, A., Hawkins, R. M., Murray, S., THOMAS, G. V., Caruso, B., Thompson, R. F., Wood, M. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04522-6 · Cited by 408
Self-citationThe DNA methylation landscape of advanced prostate cancer
Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sjöström, M., Aggarwal, R. R., Playdle, D., Liao, A., Alumkal, J. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0648-8 · Cited by 357
Self-citationA genomic and epigenomic atlas of prostate cancer in Asian populations
Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., Wang, H., Yu, Y., Yang, C., Gao, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2135-x · Cited by 353
Netto, G. J., Amin, M. B., Berney, D. M., Compérat, É., Gill, A. J., Hartmann, A., Menon, S. G., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.002 · Cited by 355
Brady, L., Kriner, M., Coleman, I. M., Morrissey, C. M., Roudier, M. P., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 310
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 297
Self-citationNyquist, M. D., Corella, A. N., Coleman, I. M., Sarkar, N. D., Kaipainen, A., Ha, G., Gulati, R., Ang, L. S., Chatterjee, P., Lucas, J. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 297
Mutational signatures: emerging concepts, caveats and clinical applications
Koh, C. C., Degasperi, A., Zou, X., Momen, S., & Nik‐Zainal, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00377-7 · Cited by 291
Zhang, C., Zhang, M., Ge, S., Huang, W., Lin, X., Gao, J. X., Gong, J., & Shen, L. (2019) · Cancer Medicine · doi:10.1002/cam4.2360 · Cited by 283
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 274
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 296
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 248
Towards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 230
Self-citationvan Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 214
Beltran, H., Romanel, A., Conteduca, V., Casiraghi, N. A., Sigouros, M., Franceschini, G. M., Orlando, F., Fedrizzi, T., Ku, S., Dann, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131041 · Cited by 196
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 202
Complexities of Prostate Cancer
Wasim, S., Lee, S., & Kim, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214257 · Cited by 225
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Vandekerkhove, G. R., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D. J., Warner, E. W., Herberts, C., Ritch, E. J., Beja, K., Loktionova, Y., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.042 · Cited by 190
Self-citationDeep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Herberts, C., Annala, M., Sipola, J., Ng, S. W. S., Chen, X. E., Nurminen, A., Korhonen, O. V., Munzur, A. D., Beja, K., Schönlau, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04975-9 · Cited by 193
Self-citationStopsack, K. H., Nandakumar, S., Wibmer, A. G., Haywood, S., Weg, E. S., Barnett, E. S., Kim, C. J., Carbone, E. A., Vasselman, S. E., Nguyen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0168 · Cited by 177
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 180
Self-citationThe landscape of chromothripsis across adult cancer types
Voronina, N., Wong, J., Hübschmann, D., Hlevnjak, M., Uhrig, S., Heilig, C. E., Horak, P., Kreutzfeldt, S., Möck, A., Stenzinger, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16134-7 · Cited by 170
Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention
Vietri, M. T., D’Elia, G., Caliendo, G., Resse, M., Casamassimi, A., Passariello, L., Albanese, L., Cioffi, M., & Molinari, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073753 · Cited by 195
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes, A. J., Samad, B., Tsui, J. L., Chew, N. W., Yan, P., Reeder, G. C., Kushnoor, D., Shen, A. S., Davidson, B. R., Barczak, A. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.004 · Cited by 170
Self-citationTargeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 182
Self-citationBiomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce‐Gallego, S., Seed, G., Llop‐Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C. M., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 158
Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 157
Landscape of Noncoding RNA in Prostate Cancer
Hua, J. T., Chen, S., & He, H. H. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.08.004 · Cited by 152
Self-citationCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 168
Alumkal, J. J., Sun, D., Lu, E., Beer, T. M., THOMAS, G. V., Latour, E. J., Aggarwal, R. R., Cetnar, J. P., Ryan, C. J., Tabatabaei, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922207117 · Cited by 146
Self-citationComprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Yachida, S., Totoki, Y., Noë, M., Nakatani, Y., Horie, M., Kawasaki, K., Nakamura, H., Saito-Adachi, M., Suzuki, M., Takai, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0669 · Cited by 161
The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer
Lancho, O., & Herranz, D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.003 · Cited by 143
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 140
Kohli, M., Tan, W. W., Zheng, T., Wang, A., Montesinos, C., Wong, C., Du, P., Jia, S., Yadav, S., Horvath, L. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102728 · Cited by 137
Aggarwal, R. R., Schweizer, M. T., Nanus, D. M., Pantuck, A. J., Heath, E. I., Campeau, E., Attwell, S., Norek, K., Snyder, M., Bauman, L. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1707 · Cited by 138
Self-citationChen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 130
Self-citationBiological Evolution of Castration-resistant Prostate Cancer
Davies, A., Conteduca, V., Zoubeidi, A., & Beltran, H. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.016 · Cited by 126
Self-citationATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
Rafiei, S., Fitzpatrick, K., Liu, D., Cai, M.-Y., Elmarakeby, H., Park, J., Ricker, C. A., Kochupurakkal, B. S., Choudhury, A. D., Hahn, W. C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3126 · Cited by 131
Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A. M., Preković, S., Wetterskog, D., Tolonen, T. T., Vuorinen, E. M., Kiviaho, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25624-1 · Cited by 123
NSD2 is a conserved driver of metastatic prostate cancer progression
Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 122
Computational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 118
Ramnarine, V. R., Kobelev, M., Gibb, E. A., Nouri, M., Lin, D., Wang, Y. Z., Buttyan, R., Davicioni, E., Zoubeidi, A., & Collins, C. C. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.040 · Cited by 121
Self-citationNguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 122
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Le, T. K., Duong, Q. H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taïeb, D., & Rocchi, P. (2023) · Cancers · doi:10.3390/cancers15205047 · Cited by 125
Yuan, J., Kensler, K. H., Hu, Z., Zhang, Y., Zhang, T., Jiang, J., Xu, M., Pan, Y., Long, M., Montone, K. T., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008641 · Cited by 116
Self-citationSignificance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Chakraborty, G., Armenia, J., Mazzu, Y. Z., Nandakumar, S., Stopsack, K. H., Atiq, M. O., Komura, K., Jehane, L. E., Hirani, R., Chadalavada, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1570 · Cited by 116
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 117
Self-citationComprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Yachida, S., Totoki, Y., Noë, M., Nakatani, Y., Horie, M., Kawasaki, K., Nakamura, H. K., Saito-Adachi, M., Suzuki, M., Takai, E., et al. (2022) · Utrecht University Repository (Utrecht University) · Cited by 112
Wang, M., Chen, J., Lu, Y., Bawcom, A. R., Wu, J., Ou, J., Asara, J. M., Armstrong, A. J., Wang, Q., Li, L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166647 · Cited by 121
Self-citationMerging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Koo, K. M., Mainwaring, P. N., Tomlins, S. A., & Trau, M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0178-2 · Cited by 109
Self-citationLotan, T. L., Kaur, H. B., Salles, D. C., Murali, S., Schaeffer, E. M., Lanchbury, J. S. S., Isaacs, W. B., Brown, R. E., Richardson, A. L., Cussenot, O., et al. (2021) · Modern Pathology · doi:10.1038/s41379-020-00731-4 · Cited by 113
Oligometastatic prostate cancer: Reality or figment of imagination?
Foster, C. C., Weichselbaum, R. R., & Pitroda, S. P. (2018) · Cancer · doi:10.1002/cncr.31860 · Cited by 105
Zhu, Y., Dalrymple, S. L., Coleman, I. M., Zheng, S. L., Xu, J., Hooper, J. E., Antonarakis, E. S., Marzo, A. M. D., Meeker, A. K., Nelson, P. S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01479-6 · Cited by 107
Genome-wide plasma DNA methylation features of metastatic prostate cancer
Wu, A., Cremaschi, P., Wetterskog, D., Conteduca, V., Franceschini, G. M., Kleftogiannis, D., Jayaram, A., Sandhu, S. K., Wong, S. Q., Benelli, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130887 · Cited by 103
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101
Homologous Recombination and the Formation of Complex Genomic Rearrangements
Piazza, A., & Heyer, W. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.10.006 · Cited by 108
Sztupinszki, Z. M., Dióssy, M., Krzystanek, M., Börcsök, J., Pomerantz, M. M., Tisza, V., Spisák, S., Rusz, O., Csabai, I., Freedman, M. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2135 · Cited by 100
Whole-genome landscape of adult T-cell leukemia/lymphoma
Kogure, Y., Kameda, T., Koya, J., Yoshimitsu, M., Nosaka, K., Yasunaga, J., Imaizumi, Y., Watanabe, M., Saito, Y., Ito, Y., et al. (2021) · Blood · doi:10.1182/blood.2021013568 · Cited by 102
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1625 · Cited by 95
Self-citationSnyder, L. B., Neklesa, T. K., Willard, R. R., Gordon, D., Pizzano, J., Vitale, N., Robling, K., Dorso, M. A., Moghrabi, W. N., Landrette, S. F., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0655 · Cited by 104
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V. M., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., THOMAS, G. V., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0134-5 · Cited by 96
Self-citationStructural Variation in Cancer: Role, Prevalence, and Mechanisms
Cosenza, M. R., Rodríguez–Martín, B., & Korbel, J. O. (2022) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120121-101149 · Cited by 99
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Sugawara, T., Baumgart, S. J., Nevedomskaya, E., Reichert, K., Steuber, H., Lejeune, P., Mumberg, D., & Haendler, B. (2019) · International Journal of Cancer · doi:10.1002/ijc.32242 · Cited by 95
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 98
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 94
Self-citationActivating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Herberts, C., Murtha, A. J., Fu, S. Y. F., Wang, G., Schönlau, E., Xue, H., Lin, D., Gleave, A., Yip, S., Angeles, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.058 · Cited by 89
Self-citationHawley, J. E., Obradović, A., Dallos, M. C., Lim, E. A., Runcie, K. D., Ager, C. R., McKiernan, J., Anderson, C. B., DeCastro, G. J., Weintraub, J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.006 · Cited by 93
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 86
Warner, E. W., Herberts, C., Fu, S. Y. F., Yip, S., Wong, A., Wang, G., Ritch, E. J., Murtha, A. J., Vandekerkhove, G. R., Fonseca, N. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3708 · Cited by 90
Self-citationDeLucia, D. C., Cardillo, T. M., Ang, L. S., Labrecque, M. P., Zhang, A., Hopkins, J. E., Sarkar, N. D., Coleman, I. M., da Costa, R. M. G., Corey, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3396 · Cited by 88
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Lundberg, A., Zhang, M., Aggarwal, R. R., Li, H., Zhang, L., Foye, A., Sjöström, M., Chou, J., Chang, K. C., Moreno-Rodriguez, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0593 · Cited by 86
Self-citationA systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
Lang, S., Swift, S. L., White, H., Misso, K., Kleijnen, J., & Quek, R. G. W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4842 · Cited by 85
Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K. G., de Barros, H. A., Alkemade, M., Bekers, E. M., Severson, T., Sanders, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0576 · Cited by 83
Self-citationLi, Y., Yang, R., Henzler, C. M., Ho, Y., Passow, C. N., Auch, B., Carreira, S., Rodrigues, D. N., Bertan, C. M., Hwang, T. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3023 · Cited by 82
Self-citationMolecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 84
Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., THOMAS, G. V., Foye, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1101 · Cited by 80
Self-citationMalihi, P. D., Graf, R. P., Rodríguez, Á., Ramesh, N., Lee, J. S. H., Sutton, R., Jiles, R., Velasco, C. R., Sei, E., Kolatkar, A. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4100 · Cited by 78
Prostate zones and cancer: lost in transition?
Ali, A., Feu, A. D., Oliveira, P., Choudhury, A., Bristow, R. G., & Baena, E. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00524-7 · Cited by 83
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 76
“Specifically, CDK12 mutation is related to tandem duplications [71].”
Xu, L., Yin, Y., Li, Y., Chen, X., Chang, Y., Zhang, H., Liu, J., Beasley, J., McCaw, P., Zhang, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012748118 · Cited by 79
Self-citationTechnical and biological constraints on ctDNA-based genotyping
Herberts, C., & Wyatt, A. W. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.001 · Cited by 78
Self-citationEftekharzadeh, B., Banduseela, V. C., Chiesa, G., Martínez-Cristóbal, P., Rauch, J. N., Nath, S. R., Schwarz, D. M. C., Shao, H., Marin-Argany, M., Di Sanza, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11594-y · Cited by 76
Ritch, E. J., Fu, S. Y. F., Herberts, C., Wang, G., Warner, E. W., Schönlau, E., Taavitsainen, S., Murtha, A. J., Vandekerkhove, G. R., Beja, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1623 · Cited by 77
Self-citationAndrogen receptor and MYC equilibration centralizes on developmental super-enhancer
Guo, H., Wu, Y., Nouri, M., Spisák, S., Russo, J. W., Sowalsky, A. G., Pomerantz, M. M., Wei, Z., Korthauer, K. D., Seo, J.-H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27077-y · Cited by 77
Self-citationHan, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 74
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 76
“Whole genome sequencing, while not clinically used today, is capable of detecting structural alterations and rearrangements that lead to dysregulation of cancerrelated genes and resistance-causing alterations(49, 80).”
Self-citationWang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 77
Self-citationWang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
Metadata
- Authors
- Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N., Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J., & Feng, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Oregon Health & Science University (US)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- University of Minnesota (US)
- University of California Davis Medical Center (US)
- University of California, Santa Cruz (US)
- Illumina (United States) (US)
- Thomas Jefferson University (US)
- University Health Network (CA)
- Duke University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- ORCID
- Quigley, David A.
- Dang, Ha X.
- Zhao, Shuang G.
- Lloyd, Paul
- Aggarwal, Rahul
- Alumkal, Joshi J.
- Foye, Adam
- Kothari, Vishal
- Perry, Marc D.
- Zhang, Li
- Zhang, Jin
- Youngren, Jack F.
- Cieslik, Marcin P.
- Parolia, Abhijit
- Beer, Tomasz M.
- Thomas, George
- Chi, Kim N.
- Gleave, Martin
- Lack, Nathan A.
- Zoubeidi, Amina
- Reiter, Robert E.
- Rettig, Matthew B.
- Witte, Owen
- Ryan, Charles J.
- Fong, Lawrence
- Kim, Won
- Friedlander, Terence
- Chou, Jonathan
- Li, Haolong
- Das, Rajdeep
- Li, Hui
- Goodarzi, Hani
- Gilbert, Luke A.
- Lara, Primo N.
- Evans, Christopher P.
- Goldstein, Theodore C.
- Stuart, Joshua M.
- Tomlins, Scott A.
- Spratt, Daniel E.
- Farh, Kyle
- Gehring, Julian S.
- Hakenberg, Jörg
- Shon, John
- Sickler, Brad
- Batzoglou, Serafim
- Knudsen, Karen E.
- He, Housheng H.
- Huang, Jiaoti
- Wyatt, Alexander W.
- Dehm, Scott M.
- Ashworth, Alan
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 3
- Pages
- 758-769.e9
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6425931
- OpenAlex
- W2884001931
- Semantic Scholar
- c72ffe522bd85597687b47e4d3db90ec72b4fc80
- Cited by
- 733
- References
- 73
- Citations by year
- 2026: 48 · 2025: 73 · 2024: 102 · 2023: 107 · 2022: 94 · 2021: 110 · 2020: 102 · 2019: 81 · 2018: 15
- FWCI
- 58.02
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-18)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Team Award (SU2C-AACR-DT0812, SU2C-AACR-DT0712)
- Movember Foundation
- Goldberg-Benioff Research Fund for Prostate Cancer Translational Biology
- Prostate Cancer Foundation Challenge
- V Foundation
- BRCA Foundation Young Investigator Award
- Department of Defense (W81XWH-16-1-0747, W81XWH-15-1-0562, PC160429, W81XWH-17-1-0192)
- Early Detection Research Network (U01 CA214170)
- Prostate SPORE (P50 CA186786, P50 CA097186)
- NIH (R01CA174777)
- NCI T32 (CA108462)
- Prostate Cancer Foundation Young Investigator Awards
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, structural variants, androgen receptor, c-Myc, tandem duplication, long non-coding RNA, DNA repair deficiency, CDK12, TP53, chromothripsis, BRCA2
- MeSH terms
- Whole Genome Sequencing, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Cyclin-Dependent Kinases, Tandem Repeat Sequences, Gene Expression Profiling, Genomics, BRCA2 Protein, Genomic Structural Variation, DNA Copy Number Variations, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
